Spatial Biology and Organoid Technologies Reveal a Potential Therapy-Resistant Cancer Stem Cell Population in Pancreatic Ductal Adenocarcinoma

A therapy-resistant CD44v9+ cancer stem cell population persists in pancreatic ductal adenocarcinoma tissues and organoid models despite treatment with cabozantinib and immunotherapy.

• Why it matters: Understanding mechanisms of treatment resistance in PDAC is crucial because the disease has a 5-year survival rate of less than 10%, and current therapies are limited by an immunosuppressive tumor microenvironment.
• What they did: The study used spatial molecular imaging, multiplex immunofluorescence, and patient-derived organoid co-cultures to analyze PDAC tissues and evaluate effects of cabozantinib combined with pembrolizumab, focusing on tumor microenvironment heterogeneity and cancer stem cell populations.
• The result: Findings reveal that a persistent, SOC-resistant CD44v9+ cancer stem cell population exists in post-chemotherapy and metastatic tissues, suggesting these cells as potential therapeutic targets to improve PDAC treatment outcomes.